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Abstract
Dasatinib, a new-generation Src and platelet-derived growth factor receptor (PDGFR) inhibitor, is currently under
evaluation in high-grade glioma clinical trials. To achieve optimum physicochemical and/or biologic properties, al-
ternative drug delivery vehicles may be needed. We used a novel fluorinated dasatinib derivative (F-SKI249380), in
combination with nanocarrier vehicles and metabolic imaging tools (microPET) to evaluate drug delivery and
uptake in a platelet-derived growth factor B (PDGFB)–driven genetically engineered mouse model (GEMM) of
high-grade glioma. We assessed dasatinib survival benefit on the basis of measured tumor volumes. Using brain
tumor cells derived from PDGFB-driven gliomas, dose-dependent uptake and time-dependent inhibitory effects of
F-SKI249380 on biologic activity were investigated and compared with the parent drug. PDGFR receptor status
and tumor-specific targeting were non-invasively evaluated in vivo using 18F-SKI249380 and 18F-SKI249380–
containing micellar and liposomal nanoformulations. A statistically significant survival benefit was found using
dasatinib (95 mg/kg) versus saline vehicle (P< .001) in tumor volume–matched GEMM pairs. Competitive binding
and treatment assays revealed comparable biologic properties for F-SKI249380 and the parent drug. In vivo,
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Significantly higher tumor uptake was observed for 18F-SKI249380–containingmicelle formulations [4.9 percentage of
the injected dose per gram tissue (%ID/g); P= .002] compared to control values (1.6%ID/g). Saturation studies using
excess cold dasatinib showed marked reduction of tumor uptake values to levels in normal brain (1.5%ID/g), consis-
tent with in vivo binding specificity. Using 18F-SKI249380–containing micelles as radiotracers to estimate therapeutic
dosing requirements, we calculated intratumoral drug concentrations (24–60 nM) that were comparable to in vitro
50% inhibitory concentration values. 18F-SKI249380 is a PDGFR-selective tracer, which demonstrates improved
delivery to PDGFB-driven high-grade gliomas and facilitates treatment planning when coupled with nanoformulations
and quantitative PET imaging approaches.
Neoplasia (2012) 14, 1132–1143
Introduction
Glioblastoma multiforme (GBM), the most common primary central
nervous system tumor, requires aggressive local therapy and adjuvant
chemotherapy to target widespread microscopic disease infiltration.
These treatment combinations, however, confer only short-term sur-
vival benefit, and alternative therapeutic strategies have been increas-
ingly incorporated into treatment planning protocols [1]. Mutations
and activation of oncogenes contribute to GBM pathogenesis [2–5],
leading to increased expression of receptor tyrosine kinases (RTKs). In
addition, platelet-derived growth factor receptor (PDGFR) and non-
receptor membrane-associated tyrosine kinases [i.e., Src family kinases
(SFKs)] serve as attractive candidates for targeted tumor imaging and
therapeutic intervention [6]. Inhibition of PDGFR leads to growth
arrest and reduced tumor invasiveness, effects mediated through SFK
activation [6–8]. Modest responses in high-grade glioma clinical trials
using first-generation single-targeted kinase inhibitors have impli-
cated several limitations relating to drug delivery, transporters, and
compensatory kinase pathways [9,10].
Dasatinib (BMS354825, 488 g/mol), a highly potent second-
generation ATP-competitive inhibitor of multiple protein tyrosine ki-
nases [11–15], including PDGFR and SFKs [15,16], reduces tumor
cell survival and proliferative and metastatic activity in vitro. In human
GBM [17,18], PDGFRα, Src, and other known dasatinib targets are
frequently activated. In this setting, dasatinib is currently being assessed
in ongoing clinical trials of newly diagnosed and recurrent GBM [1].
The investigation of such novel agents for treating central nervous
system tumors needs to consider issues relating to solubility, barrier pen-
etration, drug uptake, and intratumoral distribution. These properties
are not generally evaluated in the context of drug delivery due to the com-
plexity of biologic systems and an inability to serially monitor this process
non-invasively in the absence of drug labeling. One approach to accu-
rately assess the above tumor-specific properties is to combine quantita-
tive molecular imaging tools [i.e., micro–positron emission tomography
(microPET)], with tracer doses of radiolabeledmolecular probes or nano-
carriers. This approach permits key physiologic and tumor-specific
parameters to be defined, thus allowing pharmacologic doses to be esti-
mated for image-guided targeted drug delivery and therapy [19].
In the present study, we examined the survival benefit of dasatinib,
for the first time, in a clinically relevant platelet-derived growth factor B
(PDGFB)–driven genetically engineered mouse model of high-grade
glioma [i.e., murine glioblastoma multiforme (mGBM)] [20,21] to
confirm previously established cellular profiles of target inhibition
(i.e., PDGFRα, Src) [15]. Following synthesis of a newly modified fluo-
rinated dasatinib derivative (F-SKI249380), and before in vivo imaging
studies, we sought to determine the biologic equivalence of F-SKI249380
relative to the parent drug in terms of cell binding kinetics, dose-
response behavior, cell cycle effects, PDGFR signaling, and inhibitory
responses in tumor-derived primary glioma cell cultures. Incorpora-
tion of F-SKI249380 into micellar and liposomal nanocarriers was
then performed to investigate whether improved drug delivery and
uptake [percentage of the injected dose per gram tissue (%ID/g)]
could be achieved in relation to the native fluorinated drug in PDGFB-
driven mGBM.
Nanocarrier-encapsulated tracer preparations, along with microPET
imaging, were used to develop a rational, translatable approach for es-
timating future in vivo therapeutic dosing requirements. We highlight
the distinct advantages of using dynamic microPET imaging methods
in combination with these tracer preparations to monitor the drug de-
livery process, localize the tumor, and extract the following key prop-
erties for individualizing treatment planning protocols: kinetics of tracer
uptake and cumulative tracer concentrations.
Materials and Methods
Reagents, Antibodies, and Chemicals
Dulbecco’s modified Eagle’s medium–high glucose (DMEM-HG)
media with 1.5 g/l sodium bicarbonate, fetal calf serum (FCS), penicil-
lin, streptomycin, and Hank’s balanced salt solution (HBSS; with-
out calcium and magnesium containing 0.25% trypsin and 0.05%
EDTA) were obtained from the Core Media Preparation Facility
[Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY].
Anti-polyclonal rabbit, phospho-Erk1/2 (p-Erk1/2Thr202/Tyr204),
phospho-Akt (p-AktSer473), phospho-Src (p-SrcTyr419), phospho-p70S6
(p-p70S6Thr389), phospho-MEK1/2 (p-MEK1/2Ser217/221), Erk, Akt,
Src, p70S6, and MEK1/2 (47E6) were obtained from Cell Signaling
Technology (Danvers, MA). Goat anti-rabbit IgG, goat anti-mouse
IgG HRP conjugates, and normal rabbit IgG were procured from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti–fluorescein isothiocyanate–
Annexin V and 10× Annexin V binding buffer were obtained from BD
Biosciences Pharmingen (San Jose, CA). Propidium iodide, DNase,
RNase A, and recombinant human PDGFB were obtained from
Invitrogen (Carlsbad, CA). Monoclonal anti–β-actin (clone AC-15) was
supplied by Sigma-Aldrich (St Louis, MO). Ovomucoid and papain were
procured from Worthington Biochemical Corporation (Lakewood, NJ).
Dasatinib was obtained from US Biological (Swampscott, MA), and
fluorinated dasatinib derivatives (19F-, 18F-SKI249380) were synthesized
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in-house. Both dasatinib and/or the fluorinated dasatinib derivative were
used as competitors in these studies.
Synthesis of Chlorodasatinib (N-(2-chloro-6-methylphenyl)-
2-(6-(4-(2-chloroethyl) piperazin-1-yl)-2-methylpyrimidin-
4-ylamino)thiazole-5-carboxamide)
The chlorodasatinib precursor was prepared by chlorinating the
free base of dasatinib (BMS354825) with mesyl chloride and tri-
ethylamine. BMS354825 (21 mg, 0.043 mmol), triethylamine (12 μl,
0.086 mmol), and 1 ml of anhydrous dimethylformamide (DMF)
were added to a 5-ml screw-top vial under argon with magnetic stirring.
The vial was cooled in an ice bath for 5 minutes. Methanesulfonyl
chloride (5 μl, 0.065 mmol) was added, and the mixture was stirred
for 15 minutes, allowed to warm to ambient temperature, and stirred
for 12 hours. The reaction mixture was partitioned between 20 ml of
CH2Cl2 and 20 ml of water. The organic layer was washed with water
(2 × 10ml) and brine (10 ml), dried over Na2SO4, filtered, and concen-
trated. The residue was resuspended in a small amount of CH2Cl2 and
purification by gradient flash chromatography (SiO2, 0% to 10%
MeOH/CH2Cl2) yielded 12 mg (55%) of chlorodasatinib:
1H NMR
(DMSO-d6), δ = 11.46 (s, 1H), 9.86 (s, 1H), 8.21 (s, 1H), 7.38
(dd, 1H, J = 7.6, 1.3 Hz), 7.29 to 7.22 (m, 2H), 6.04 (s, 1H), 3.71 (t,
2H, J = 6.7 Hz), 3.51 (br s, 4H), 2.68 (t, 2H, J = 6.6 Hz), 2.52 (br s,
4H), 2.40 (s, 3H), 2.23 (s, 3H); mass spectrometry-electrospray
ionization (MS-ESI) theory, m/z = 506.13 [M + H]+, found: 506.1;
HPLC, tR = 12.0 minutes [Phenomenex Gemini C18, 250 × 4.6 mm,
gradient 70% A (20 mM KH2PO4, pH 4.1)/30% B (CH3CN) to
20% A/80% B, 1 ml/min, λ = 254 nm].
Synthesis of 18F-SKI249380
Cyclotron-produced [18F]-HF in [18O]-water was transferred to a
solution containing 120 μl of 0.25 M K2CO3 (20 μmol) and 10 mg
(2.7 μmol) of Kryptofix (2.2.2) in 0.5 ml of CH3CN in a 10-ml Reacti-
Vial. Water was removed azeotropically with CH3CN (3 × 0.5 ml)
at 105 to 110°C. Anhydrous [18F] KF/K2CO3, complexed with
Kryptofix, was dissolved in 0.4 ml of CH3CN, added to 3.0 mg
(2.0 μmol) of chlorodasatinib, and heated (sealed) on a heating block
(90°C, 45 minutes). The reaction mixture was cooled to room tem-
perature and diluted with 1 ml of HPLC solvent (20% CH3CN). The
product was purified using HPLC [20%→80% CH3CN in 50 mM
NaOAc buffer (pH 5), 100 × 21.2 mm Gemini NX C18 column].
The product-containing fraction at tR = 12.2 minutes was collected
and concentrated to near dryness by rotary evaporation. The product
was resuspended in 500 μl of saline and filtered through a 45-μm filter
into a sterile vial. Total time of radiosynthesis was about 120 minutes
from end of bombardment. Decay-corrected radiochemical yields were
18 ± 5% (n = 7) over two steps based on starting [18F]-fluoride, and
specific activity ranged from 300 to 600 mCi/μmol (n = 3). No sig-
nificant contaminants were present in the final product.
Generation of a PDGFB-driven Glioma Cell Line
Primary mouse PDGFB-driven mGBM cell lines were generated
from freshly isolated mGBM. Briefly, tumors were dissected and
collected in 1× HBSS containing 0.6% glucose. Tissues were enzy-
matically digested in 1× HBSS containing 12% papain and 10 μg/ml
DNase (37°C, 15 minutes) and subsequently inactivated with ovomucoid
(1 mg/ml) as previously described [22]. Single-cell suspensions were
prepared and cultured in DMEM-HG/1.5 g/l sodium bicarbonate
medium supplemented with 10% FCS.
Generation of PDGFB-driven mGBM
All animal experiments were done in accordance with protocols
approved by the Institutional Animal Care and Use Committee of
MSKCC and followed National Institutes of Health guidelines for ani-
mal welfare. At 4 to 6 weeks of age, Nestin-tva/ink4a-arf−/− mice (n =
45) were injected intracranially with 4 × 104 DF-1 cells (ATCC,
Manassas, VA) transfected with and producing Replication Compe-
tent ASLV long terminal repeat with Splice acceptor−PDGFB retro-
viral vector and using a stereotactic fixation device (Stoelting, Wood
Dale, IL), as described previously [23]. Mice were monitored carefully
for symptoms of tumor development (hydrocephalus, lethargy, and
head tilt).
NIH 3T3 Fibroblasts Expressing PDGFRα-myc
Fibroblasts expressing the PDGFRα-myc receptor were generated
by infecting NIH 3T3 cells with retroviral expression vectors encoding
PDGFRα [18]. Cells were grown and maintained in DMEM-HG/
1.5 g/l sodium bicarbonate medium supplemented with 10% calf serum
(Colorado Serum Company, Denver, CO).
In Vitro Receptor Binding Assays
Competitive PDGFR binding studies and kinetic analyses were
performed by co-incubating PDGFB-driven mGBM cells with 19F-
dasatinib (19F-SKI249380) or dasatinib (BMS354825) and adding
18F-dasatinib (18F-SKI249380). Briefly, triplicate samples of 18F-
dasatinib (18F-SKI249380; 20,000 cpm) and increasing amounts
(0.001–1000 nM) of non-radiolabeled competitor were mixed with
cells on an orbital shaker (1 hour, 25°C). Cells were then isolated
by rapid filtration, washed with ice-cold TBS using a cell harvester
(Brandel, Gaithersburg, MD), and counted, along with suitable blanks,
using a γ-counter (Perkin Elmer 1480Wizard 3,Waltham, MA). Non-
specific and specific uptake of 18F-SKI249380 was determined, the
former in the presence of 1000 nM 19F-SKI249380. These data were
plotted against the concentration of cold competitors, and sigmoidal
displacement curves were analyzed by a least-squares fitting algorithm
(Origin, Northampton, MA). Scatchard analysis of the saturation bind-
ing kinetic curve for SKI249380 yielded the equilibrium dissociation
constant, K d, and total number of available bound receptor sites per
cell, Bmax.
Cell Viability Assays with 19F-SKI249380
mGBM cells, expressing PDGFB-encoding viruses, were seeded into
24-well culture plates. In one set of treatment studies, 19F-SKI249380
was added to 6.0 × 104 cells/well in media supplemented with 10%
FCS over a range of concentrations (2.5–500 nM) for 72 hours,
whereas in a second set of studies, two concentrations (10 and 50 nM)
were added to 2.5 × 104 cells/well every 48 hours over a range of incu-
bation times (0–8 days). The percent (%) cell viability was determined
after trypsinization using a Vi-Cell series viability analyzer (Beckman
Coulter, Inc, Fullerton, CA). In a parallel set of experiments, mGBM
cells were made quiescent under serum-deprived conditions (DMEM/
1.5 g of sodium bicarbonate containing 0.2% FCS) at 37°C for
96 hours before treatment for G0/G1 phase synchronization. Cells
then underwent a medium change to one containing 0.2% FCS
(control media), 10% FCS, or 0.2% FCS supplemented with PDGF
(25 ng/ml) and were subsequently incubated at 37°C with or without
19F-SKI249380. Each experiment was performed in triplicate.
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Cell Cycle Analysis
G0/G1 phase–synchronized mGBM cells were incubated for 72 hours
using a range of 19F-SKI249380 concentrations (0–1000 nM) after
changing the medium to 10% FCS. Following trypsinization, cells
were centrifuged (1200 rpm, 5 minutes), and the pellet was suspended
in phosphate-buffered saline (PBS), followed by fixation with 70%
ethanol (0.5–1 hour, 4°C). Cells were successively resuspended in 1 ml
of PBS containing 1% FCS and 0.1% Triton X-100, 200 μl of PBS
containing 25 μg/ml propidium iodide, and 100 μg/ml RNase A (4°C,
60 minutes). Cell cycle analysis was performed by flow cytometry
(FACSCalibur; Becton Dickinson, Mountain View, CA) and Phoenix
FlowMultiCycle software (Phoenix Flow Systems, Inc, San Diego, CA).
Apoptosis and Necrosis
mGBM cells, initially grown under serum-deprived conditions,
were subsequently incubated with 19F-SKI249380 (0–1000 nM) for
72 hours in 10% FCS–supplemented media. After trypsinization, cells
were centrifuged (1200 rpm, 5 minutes) and resuspended in 200 μl of
1× Annexin V binding buffer. The solubilized pellet (100 μl) was
incubated in the dark (25°C, 15 minutes) with 5 μl of fluorescein
isothiocyanate–Annexin V and 2.5 μl of propidium iodide (50 mg/ml),
followed by addition of 100 μl of 1× Annexin V binding buffer for
determination of the apoptotic cell fraction (%) using flow cytometry
and FloJo analysis software (v. 8.8; Tree Star, Ashland, OR).
Western Blot
As above, mGBM cells were made quiescent and grown under
serum-deprived conditions. The medium was then changed to 10%
FCS or 0.2% FCS supplemented with 25 ng/ml PDGF, and 150 nM
19F-SKI249380 was added over a range of time intervals (5–60 min-
utes). Cells were rinsed twice in ice-cold PBS and collected by tryp-
sinization, and the pellet was resuspended in lysis buffer [10 mM
Tris (pH 8.5), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100;
ACROS Organics, Fair Lawn, NJ], 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), Complete protease inhibitors (Roche,
Indianapolis, IN), and phosphatase inhibitor cocktails 1 and 2 (Sigma-
Aldrich). Lysates were centrifuged (10 minutes, 4°C). Protein concen-
trations were determined by the bicinchoninic acid assay (Thermo
Scientific, Rockford, IL). A protein aliquot (30–50 μg) of each fraction
was separated by 4% to 12% gradient SDS–polyacrylamide gel electro-
phoresis and transferred to a polyvinylidene fluoride (PVDF) membrane
(Invitrogen). Membranes were blocked with 5% non-fat dry milk
(Bio-Rad, Hercules, CA) in TBS–0.1%Tween and signal visualized
by enhanced chemiluminescence (Thermo Scientific) after applying
primary (1:1000) and secondary (1:2000–1:5000) antibodies.
Immunoprecipitation
mGBM cells were grown under serum-deprived conditions. The me-
dium was then changed to 10% FCS or 0.2% FCS with 25 ng/ml
PDGF, and 250 nM 19F-SKI249380 was added for 10 minutes. After
cells were lysed in 1% NP-40 lysis buffer [50 mM Tris (pH 8.0),
50 mM NaCl, 5 mM EDTA, 1% NP-40, protease inhibitors, and
phosphatase inhibitors], lysates were incubated (2 hours, 4°C) with
anti–c-myc agarose Affinity gel (Sigma-Aldrich), followed by multiple
washings with the same buffer. Immunoprecipitated proteins were re-
solved by 5% SDS–polyacrylamide gel electrophoresis and analyzed
by Western blot (WB) analysis with phosphotyrosine (Cell Signaling
Technology), c-myc (clone-9E10; Sigma-Aldrich), and PDGFRα (Cell
Signaling Technology) antibodies using enhanced chemiluminescence
for visualization.
Survival Studies
Three weeks after intracranial inoculation, gradient echo images of
brain tumors (n = 16) were acquired in the coronal plane on a 4.7-Tesla
magnetic resonance imaging (MRI) scanner (Bruker Biospin, Billerica,
MA) using a birdcage coil and the following MRI parameters: TR =
2500 ms, TE = 50 ms, field of view = 3 × 2 cm, slice thickness (with
interslice distance = 0.7 mm) = 0.7 mm, matrix = 256 × 128, NEX =
28. Mice were anesthetized using 2% isoflurane anesthesia in oxygen
during the scan period. Three-dimensional region-of-interest (3D-
ROI) analyses (Paravision 4.0 software; Bruker) of brain tumor mice
were performed to assess tumor volumes; volume-matched pairs of
mice were assigned to either treatment or control groups for sur-
vival studies. Tumor volumes (mm3) were computed on sequential
MRI slices by summing the products of the slice areas and slice thick-
nesses over the full extent of the tumor. Mice were orally gavaged with
dasatinib (95 mg/kg) or saline vehicle (200 μl) for 10 consecutive days,
and daily weights were recorded. At treatment termination, all mice
underwent repeat MRI to assess changes in tumor volumes. Tumor
volume ratios were computed by dividing post-treatment (day 10) by
pre-treatment (day 0) values for individual mice and as cohort averages.
All mice were monitored daily, during, and following treatment and
sacrificed for lethargy, hunched appearance, respiratory distress, >15%
body weight loss, or neurologic impairment.
Micellar Formulated 18F-SKI249380
Monomers or polyethylene glycol (PEG) 3400–distearoylphospha-
tidylethanolamine (DSPE) spontaneously formed micelles on the order
of 10 nm in diameter in the absence of drug loading, with DSPE lipid
chains comprising the hydrophobic core and PEG chains coating the hy-
drophilic surface of the micelle. After 18F-SKI249380 loading of micelles,
their average size increased to 50 nm in diameter. 18F-SKI249380 was
hydrated with 0.9% NaCl and PEG3400-DSPE (30 minutes at 60°C).
Liposomal Formulated 18F-SKI249380
Lipid stock solutions were prepared in chloroform to obtain the
desired composition. Solvent was removed under a gentle stream of
nitrogen, and the lipid residue was maintained under reduced pressure
for at least 2 hours. Multilamellar liposomes (PC/Chol, 70/30 mol/
mol) were formed by hydrating dry lipids at room temperature with
1 ml of PBS containing 1 to 2 mCi 18F-SKI249380, facilitating its
encapsulation into liposomes, and yielding a lipid concentration of
20 mM. Large unilaminar vesicles were obtained by extruding multi-
lamellar dispersions 19 times through a 100-nm pore-size polycarbon-
ate membrane (Nucleapore, Pleasanton, CA) with a Mini Extruder
(Avanti Polar Lipids, Alabaster, Alabama).
Characterization of Nanocarriers
Sizemeasurements were obtained using dynamic light scattering (DLS,
Malvern Nano-S; Malvern Instruments, Worcestershire, United King-
dom). Measurements were based on differences in light backscattering
properties of different size particles. To evaluate the critical micellar
concentration (CMC), we sized micelles over a range of concentrations
[24]. The radiolabeled dasatinib-loading densities of micelles and lipo-
somes were calculated using the specific activities of 18F-SKI249380,
the overall activity of dasatinib nanocarriers (kcps), and the total amount
of lipid.
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MicroPET Imaging
Imaging was performed on a dedicated small-animal PET scanner
(Focus 120 microPET; Concorde Microsystems, Knoxville, TN).
PDGFB-driven mGBM mice (n = 20) were maintained under 2% iso-
flurane anesthesia in oxygen during the scan. One-hour list-mode
acquisitions were initiated at the time of intravenous (i.v.) injection
of 1.1 to 1.5 × 107 Bq of the fluorinated dasatinib derivative, 18F-
SKI249380 (n = 3), or 18F-labeled dasatinib nanocarriers in tumor-
bearing mice (n = 5 mice each for micelles and liposomes). In addition,
18F-SKI249380 was injected i.v. into non–tumor-bearing age-matched
controls (n = 4). Voxel count rates in reconstructed images were con-
verted to activity concentrations (i.e., %ID/g) using a measured system
calibration factor. 3D-ROI analyses of reconstructed images (ASIPro
software; Concorde Microsystems) yielded mean, maximum, and SD
of tumor uptake.
In Vivo PDGFR Blocking Studies
Thirty minutes after i.v. injection of a single pharmacologic
dose of non-radiolabeled dasatinib (∼5 μM, 200 μl), tracer doses of
18F-SKI249380 were administered i.v. (n = 3), followed by 1-hour
list-mode PET acquisitions. Average “post-block” tumor activity–
concentration values were determined and compared with correspond-
ing “pre-block” values derived 3 days earlier in the same animals.
Biodistribution Studies
mGBM mice (n = 9 mice; three mice per time point) were
i.v. injected with a micellar nanoformulation of 18F-SKI249380
(∼100 μCi/mouse) before 30-minute list-mode PET acquisitions at
15 minutes, 1 hour, and 4 hours post-injection (p.i.). Ex vivo %ID/g
values, corrected for radioactive decay to the time of injection, were
measured by sacrificing mice at 4 hours p.i. and harvesting, weighing,
and counting blood, tumor-bearing brain, and organs in a scintilla-
tion γ-counter. The small brain size of the mice and the diffuse,
infiltrative nature of these tumors limited differentiation of tumors
from the normal brain in the same animal. Image-derived %ID/g
values of tumor-bearing brain, liver, heart, and muscle were addition-
ally determined at each time point by performing 3D-ROI analyses;
measurements at 4 hours were correlated with ex vivo values.
Statistics
Competitive binding assays and corresponding Scatchard plots were
analyzed by linear regression analyses (Microsoft Excel 2007) to de-
rive receptor binding parameters [K d, Bmax, and 50% inhibitory con-
centration (IC50)]. Goodness-of-fit values (R
2) and their associated
P values are indicated. The Mann-Whitney U test was used to test
statistical significance of tumor volume ratios and imaging data, expressed
as the mean tumor uptake value (%ID/g) ± SD. We assigned statistical
significance for all tests at P < .05. Correlation of image- and γ-counter–
derived %ID/g values was performed using a least-squares regression
algorithm (SigmaPlot, Systat, v. 11.0). The Kaplan-Meier method and
log-rank test were used to evaluate survival curves. Survival of eachmouse
was recorded as the length of time from treatment initiation to demise.
Results
Competitive PDGFRα Receptor Binding of Dasatinib and
19F-SKI249380 to mGBM Cells
The radiotracer, 18F-SKI249380, previously prepared by a two-step
procedure [15], was synthesized as a newly modified one-step approach
using the chlorinated analog of dasatinib (Figure 1). The binding spec-
ificity of 18F-SKI249380 to mGBM cells was investigated in the pres-
ence of non-radiolabeled competitors, 19F-SKI249380 and dasatinib.
Displacement curves were found to be equivalent over a range of con-
centrations (Figure 2A). The IC50 values were similar at 10.5 ± 2.8 nM
for 19F-SKI249380 and 13.6 ± 2.1 nM for dasatinib. The saturation
binding data and Scatchard transformation (Figure 2B) of 18F-
SKI249380 binding to mGBM cells yielded a K d of 6.3 ± 0.5 nM
and a Bmax of 1.2 × 10
6 ± 1.9 × 104 (Figure 2B, inset).
Alterations in mGBM Cell Viability and Growth Rate with
Dasatinib and 19F-SKI249380
Cultured PDGFB-driven mGBM cells were monitored for reduc-
tions in viability and growth rate following exposure to two doses of
dasatinib or 19F-SKI249380 over a range of concentrations and incu-
bation times. Dose-response curves, 120 hours after seeding, revealed a
concentration-dependent inhibition below about 150 nM. Net viabil-
ity losses averaged about 80% using at least 50 nM concentrations of
either agent. Beyond 150 nM, no such dependency was observed
(Figure W1A). On the basis of these data, IC50 values of 9 and 12 nM
were computed for dasatinib and 19F-SKI249380, respectively. In ad-
dition, net growth inhibition was relatively constant for cells incu-
bated with about 50 nM 19F-SKI249380 or dasatinib (replaced every
48 hours) over an 8-day period (Figure W1B). Up to 85% inhibition
was seen at 50 nM relative to that at 10 nM; at this latter concentra-
tion, a net increase in cell number was noted over time. On the basis
of equivalent dose-response and competitive binding data measured for
dasatinib and 19F-SKI249380, the fluorinated derivative was used for
subsequent in vitro and in vivo testing.
mGBM Viability Loss with 19F-SKI249380 in
PDGFB-supplemented Media
Initial maintenance of cells under serum-deprived conditions en-
abled G0/G1 synchronization of the majority of mGBM cells before
assessing biologic response to different media conditions. Addition of
10% FCS to G0/G1 phase–synchronized cells led to a quadrupling of
cell number relative to that for control media (Figure W1C), whereas
0.2% FCS supplemented with 25 ng/ml PDGFB ligand resulted in a
doubling of cell number (Figure W1D), likely due to greater growth
factor enrichment of serum-supplemented media. Progressive viability
losses were observed following addition of increasing 19F-SKI249380
concentrations to 10% FCS–supplemented cells; losses were greater
in the presence of PDGF-supplemented media. After exposure to
150 nM 19F-SKI249380, cell survival was reduced by factors of 2
and 6 for 10% FCS (Figure W1C )– and PDGF-supplemented (Fig-
ure W1D) media, respectively.
Influence of 19F-SKI249380 on Cell Cycle and
Apoptosis of mGBM Cells
To analyze the effect of 19F-SKI249380 on the cell cycle and apop-
tosis, we incubated G0/G1 phase–synchronized mGBM cells for
72 hours over a range of 19F-dasatinib concentrations (0–1000 nM)
in 10% FCS–supplemented media. Over this range, the percentage
of cells in the G1 phase rose by 31%, whereas a corresponding 67%
decline was seen in the proliferative or S phase of the cell cycle. A
smaller drop (∼40%) was noted in the G2 phase (Figure W2A). No
significant change in the percentage of cells in the G1 or S phase was
seen for 19F-SKI249380 concentrations of 200 nM or higher. The
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fraction of cells undergoing apoptotic cell death before and after expo-
sure to a range of 19F-SKI249380 concentrations is seen to increase
by more than a factor of 2 for order of magnitude changes in concen-
tration, as shown in Figure W2B along with scatter plots at three
representative concentrations. Further, cleaved poly (ADP-ribose) poly-
merase (PARP) protein was expressed onWBs for 19F-SKI249380 con-
centrations of 250 nM and higher (data not shown). Taken together,
these data indicate G1 arrest with significant inhibitory effects on cell
proliferation, along with a smaller cellular apoptotic component.
Inhibitory Effects of Dasatinib on PDGFRα and
PDGFR-mediated Signaling
The binding of the PDGFB ligand to its receptor and subsequent
receptor autophosphorylation at tyrosine residues is known to rap-
idly activate multiple signaling cascades and downstream pathway
intermediates (Figure 3A), including Ras–mitogen-activated protein
signaling, which induces activation of Raf/MAPK/Erk kinase (MEK)/
Erk and phosphatidylinositol 3-kinase/Akt pathways [Akt, mammalian
target of rapamycin (mTOR), S6K] [25–27], as well as SFKs [28–30]
(Figure 3A). To determinewhether 19F-SKI249380 inhibited activation
of PDGFR-mediated signaling, we treated serum-deprived NIH 3T3
cells, expressing myc-tagged PDGFRα, with 250 nM 19F-SKI249380
in the presence of 10% FCS or 0.2% FCS supplemented with PDGF
ligand; non-treated and serum-deprived cells without PDGF served as
controls. Immunoblot analysis of proteins, derived from the resulting
immunoprecipitated lysates and analyzed byWB using phosphotyrosine,
c-myc, and PDGFRα antibodies, demonstrated phosphorylation of tyro-
sine residues on PDGFRα, induced by 10% FCS or 0.2% FCS with
PDGF ligand (Figure 3B). This result was not seen in treated cells incu-
bated with 10% FCS, 0.2% FCS supplemented with PDGF ligand, or
serum-deprived cells. WBs of lysates immunoprecipitated with myc
antibody revealed that the amounts of protein in the samples were equiv-
alent and that PDGFRα expression was present in lysates incubated
with anti-PDGFRα antibody (Figure 3B). Collectively, these results sug-
gested that 19F-SKI249380 inhibits phosphorylation of PDGFRα.
In mGBM cells, downstream signaling pathways were also altered by
the inhibition of PDGFR phosphorylation with 19F-SKI249380. WB
analyses of untreated cell lysates revealed activation of pathway inter-
mediates in cells supplemented with 10% FCS or PDGF ligand. Treat-
ment with 150 nM 19F-SKI249380 showed subsequent inhibition
of expression levels over a range of incubation times (Figure 3C ). In
cells incubated with 0.2% FCS/PDGF ligand or 10% FCS, there
was a marked reduction in the phosphorylation levels of phospho-Rous
sarcoma oncogene homolog (pSrc), phospo-MAPK/Erk kinase
(pMEK), phospho-extracellular signal-regulated kinase (pERK), and
phospho-AKT8 virus oncogene cellular homolog (pAkt) within 5 min-
utes of 19F-SKI249380 exposure; these levels did not vary substantially
Figure 1. Schematic of the synthesis of 18F-SKI249380 from dasatinib. BMS354825 is chlorinated with mesyl chloride and triethylamine.
The resulting chlorodasatinib precursor is radiofluorinated using no carrier–added [18F]KF·Kryptofix [2.2.2] complex.
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among these different media conditions. A sustained reduction (up to
72 hours) in pSrc expression was observed (data not shown). By con-
trast, a decrease in S6K phosphorylation levels was not seen for about
30 minutes post-treatment.
Survival Benefit of Dasatinib in PDGFB-driven mGBM
MRIs were acquired before and after 10 consecutive days of orally
gavaged saline vehicle or dasatinib treatment (Figure 4A). Daily weight
measurements of mice revealed no significant weight fluctuation for
the dasatinib-treated group over the treatment interval. Tumor volume
ratios were computed for each mouse; mean values showed a statisti-
cally significant decrease in magnitude for dasatinib-treated mice versus
controls (P < .001, Figure 4B). Tumor volume ratios of volume-
matched mouse pairs show appreciable differences within each pair
(Figure 4C). Pre-treatment tumor volumes are indicated above each
column. Survival was monitored in all mice following the end of treat-
ment. Mice gavaged with saline vehicle survived 14 to 17 days post-
treatment (mean, 15.5 days), whereas dasatinib-gavaged mice survived
18 to 30 days (mean, 25.75 days; P < .001, Kaplan-Meier Survival
analysis; Figure 4D).
Micelle- and Liposome-encapsulated 18F-SKI249380 as
Suitable Drug Delivery Vehicles
18F-SKI249380 was loaded into PEGylated water-soluble nano-
carriers, and the resulting platforms were characterized by DLS. Aver-
age diameters of micelle and liposome formulations of 18F-SKI249380
were 50 and 120 nm, respectively (Figure W3A). The size distribution,
as determined by DLS, is presented according to the percentage of
backscattered intensity (Figure W3B). Fitted curves of micelle size dis-
tribution and activity are presented as a function of increasing PEG-
phosphoethanolamine (PEG-PE) concentration (Figure 5A). The data
derived from these curves, namely, the PEG-PE concentration at which
micelle size no longer increases (slope = 0), as well as the value at which
micelle activity initially increases (slope > 0), were used to estimate a
CMC of PEG-PE dasatinib < 10 μM. The CMC is defined as the con-
centration of amphiphilic molecules above which micelles can form and
incorporate drug molecules; below this level, micelles will degrade, and
the drug will be rapidly released. In addition to nanocarrier size, loading
densities of 18F-SKI249380 [drug/lipid (mol/mol) ratio] were found to
be 1/233 and 1/2000 (mol/mol) for micelles and liposomes, respectively
(Figure 5B). Yields of encapsulated 18F-SKI249380 are also shown.
Dynamic PET Imaging of 18F-SKI249380 Nanoformulations
Differential uptake of unencapsulated 18F-SKI249380, as well as
of micellar and liposomal 18F-SKI249380 formulations, was investi-
gated in glioma- and non–glioma-bearing mice (controls) by microPET
imaging. Representative coronal images from glioma-bearing mice
administered non-encapsulated and nanoformulated 18F-SKI249380
revealed uptake of the radiotracer in the majority of mice over a 1-hour
time period; no appreciable uptake was observed in control mice
Figure 2. In vitro competitive PDGFRα receptor binding kinetics with 19F-SKI249380, dasatinib, and 18F-SKI249380 in mGBM cells using
a range of concentrations (0.001–1000 nM). (A) High affinity and specific binding of 18F-SKI249380 to mGBM cells after co-incubating with
19F-SKI249380 or dasatinib and γ-counting. (B) Saturation binding kinetics of 18F-SKI249380 to mGBM cells. The inset shows Scatchard
analysis of binding data, plotting the ratio of the concentration of receptor-bound (B) to unbound (or free [F]) radioligand or the bound-to-
free ratio (B/F) versus the receptor-bound receptor concentration; the slope corresponds to the K d and x-intercept corresponds to receptor
concentration. Schematics of BMS354825 (dasatinib) and the fluorinated dasatinib derivative, F-SKI249380, are shown.
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(Figure 6A). Injection of unencapsulated 18F-SKI249380 resulted in an
average tumor uptake of 3.4 ± 0.57%ID/g, as compared with 1.6 ±
0.39%ID/g in non–tumor-bearing brains. Micelle and liposome 18F-
SKI249380 formulations were prepared. No adverse reactions were
observed following i.v. administration of these formulations. Average
micelle and liposome 18F-SKI249380 tumor uptake values of 4.9%
ID/g ± 0.85 (P = .002) and 3.5%ID/g ± 0.57 (P = .014), respectively,
were found to be significantly greater than that in the brains of control
animals (Figure 6B). Differences between average micelle and liposome
uptake (P = .016), as well as between average micelle and unencapsu-
lated 18F-SKI249380 uptake (P = .052), were also statistically signifi-
cant. There was no significant difference between the average uptake
values for liposomes and unencapsulated 18F-SKI249380.
In vivo blocking studies were performed to evaluate receptor spec-
ificity. Single pharmacologic doses of non-radiolabeled dasatinib
were injected 30 minutes before i.v. injection of 18F-SKI249380 and
dynamic PET. Significant suppression of tumor uptake values was
observed for the post-block time-activity curve (TAC) compared to
baseline (pre-block) TAC values and was similar to that found for
non–tumor-bearing mice. These findings suggested that receptor bind-
ing was fully saturated, preventing further 18F-SKI249380 uptake
(Figure 6C). The pre-block TAC in tumor-bearing mice showed a rise
in %ID/g over time, reaching its previously reported value at about
30 minutes p.i.
On the basis of the specific activity of radiolabeled nanocarriers
(i.e., 1.1–2.2 × 1010 Bq/μmol) and the administered activity (i.e.,
1.1–1.5 × 107 Bq), the total amount of injected 18F-SKI249380 was
found to range from 0.5 to 1.3 nmol. Together with the maximum
tumor uptake for i.v.-injected micellar formulations (i.e., 4.9%ID/g
at 1 hour), this yields intratumoral concentrations ranging from 24
to 64 pmol/g (or 24–60 nM). These concentrations are of the order
of the 19F-SKI249380 IC50 value of 11 nM, determined from com-
petitive binding assays. That the minimum tumor concentration is
comparable to the IC50 value for this delivery system suggests that, as
an initial approximation, at least two doses of inhibitor may be needed
to achieve significant tumor cell kill (i.e., reduce tumor cell survival to
Figure 3. In vitro dasatinib treatment exhibits an inhibitory effect on PDGFR receptor activity and shows targeted inhibition of phosphor-
ylated Src, MEK, Erk, Akt, and p70S6. (A) Schematic demonstrating multiple downstream PDGFR signal transduction pathways. (B)
Lysates from NIH 3T3 cells expressing PDGFRα-myc were immunoprecipitated with myc antibody. WBs were probed for the presence
of phosphotyrosine (upper panel), myc protein (middle panel), or PDGFRα (lower panel). Before treatment with 250 nM 19F-SKI249380,
cells were cultured in 0.2% FCS (lanes 1 and 4), 0.2% FCS/PDGF (lane 5), or 10% FCS (lane 2); after treatment in 10% FCS (lane 3) or
0.2% FCS/PDGF (lane 6). (C) Phosphorylation of Src, MEK, Erk, Akt, and p70S6 was assessed by WB for cells in 0.2% FCS, 10% FCS, or
0.2% FCS with/without PDGF and before and after the addition of 150 nM 19F-SKI249380 for fixed incubation times. β-Actin was em-
ployed as a loading control. Representative of three independent experiments.
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25% or less). Studies are underway to further characterize pharmaco-
kinetic parameters and optimize dose-response in vivo.
Net Accumulation of Micellar 18F-SKI249380 in mGBM
Biodistribution and blood, renal, and hepatobiliary clearance were
evaluated for i.v. tracer doses of micellar 18F-SKI249380 to glioma-
bearing mice, as this formulation resulted in the highest tumor up-
take and was well tolerated. Image-derived maximum uptake values
in tumor-bearing brain only decreased by about 35% over a 4-hour
time period p.i.; an average uptake value of 2.03%ID/g was mea-
sured at 4 hours (Figure W4A). High, but progressively decreasing,
hepatobiliary activity was found over the imaging period. At 4 hours
Figure 5. In vitro lipid formulations of 18F-SKI249380 for PDGFR targeting and characterization. (A) Fitted curves formicelle nanoformulations
of 18F-SKI249380 activity (kcps) and size (nm) as a function of PEG-PE concentration. The CMC (blue line), 18F-SKI249380-to-lipid loading
efficiency (1:20max), and maximum diameter (red line, up to 100 nm) are derived. (B) Nanocarrier size, respective yields, and 18F-SKI249380
loading densities.
Figure 4. Volume-matched pairs of mice with PDGFB-driven mGBM show a survival benefit after gavage with dasatinib. (A) MRIs of brain
tumors (white arrows) before and after administration of dasatinib or saline vehicle. (B) Graphical summary of average tumor volume ratios
for treated and control groups (Mann-Whitney U test, P< .001). (C) Tumor volume ratios at 10 days post-treatment relative to pre-treatment
values for individual pairs of volume-matched mice assigned to either treatment or control groups. Italicized numbers above each bar rep-
resent pre-treatment tumor volumes (mm3) of mice. (D) Survival data demonstrating a statistically significant survival benefit of dasatinib
versus saline vehicle for doses of 95 mg/kg (P < .001).
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p.i., image-derived uptake values over the liver region (∼1.5%ID/g)
were found to correspond with uptake values for ex vivo gamma-
counted specimens (∼2.5%ID/g). High uptake values were measured
in harvested intestine, spleen, and bone (Figure W4B). Blood data are
approximated by ROI measurements over the heart. Image-derived
renal uptake values were unable to be determined as no evident activ-
ity was seen over these regions. At 4 hours p.i., a statistically significant
correlation was found between image-derived and ex vivo uptake values
for liver, heart, tumor-bearing brain, and muscle (r = 0.98, P < .02;
Figure W4B, inset).
Discussion
Dasatinib is an oral inhibitor of multiple RTKs, including PDGFR and
non-receptor membrane-associated Src tyrosine kinase [11,14]. Nearly
all human malignant gliomas demonstrate amplification and over-
expression of PDGFRα [31,32], resulting from autocrine stimulation
of malignant cells [4,5,9,21]. PDGFR activation in GBMs leads to
interactions with Src binding domains, in turn, increasing Src activity
[6] and promoting proliferation, invasion, and vasculogenesis [33]. Pre-
clinical evidence suggests that Src is frequently phosphorylated in GBM
cell lines and activated in human GBM [17,34]. Further, downstream
signaling through phosphatidylinositol 3-kinase and mitogen-activated
protein pathways is operative, promoting tumorigenesis, proliferation,
and angiogenesis.
Dasatinib inhibits Src kinase in multiple cancer cell lines, including
melanoma and glioma xenograft models [8,35,36]. In this study, we
show that a newly modified fluorinated dasatinib derivative does not
alter in vitro receptor binding kinetics, specificity, or inhibitory activity
in PDGFB-driven primary mGBM cells, relative to dasatinib. 19F-
SKI249380 and dasatinib were found to similarly modulate biologic
activity over a range of concentrations and time intervals, which resulted
in comparable IC50 values in the low nanomolar range, equivalent to
Figure 6. In vivo dynamic PET imaging of selective targeting and uptake of unencapsulated and nanoformulated 18F-SKI249380 in
mGBM. (A) Representative axial microPET images at 1 hour p.i., demonstrating uptake of unencapsulated 18F-SKI249380 and micelle-
or liposome-formulated 18F-SKI249380 in tumor-bearing brains (arrows) as against non–tumor-bearing (control) brain (arrowhead). (B)
Graphical summary of tumor uptake values (%ID/g) for treatment and control groups. (C) Representative sagittal microPET brain images
from control and tumor-bearing (arrows) animals i.v. injected with 18F-SKI249380, the latter before (pre-block) and after (post-block)
blocking with pharmacologic doses of dasatinib. Corresponding 1-hour TACs are shown. Each bar represents mean ± SD. One-tailed
Mann-Whitney U tests demonstrated statistical significance at the P ≤ .05 level for micelles (*P = .002) and liposomes (**P = .014)
relative to controls, as well as between micelles and liposomes (***P = .016).
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those seen with other cell lines [16]. Progressive viability losses, observed
with increasing 19F-SKI249380 concentrations to serum-supplemented
cells, were found to be higher with PDGF-supplemented media.
Although previously tested in glioma cell lines and xenografts [7,8],
dasatinib inhibition of RTKs, non-RTKs, and other phosphorylated
pathway intermediates have not been investigated in primary tumor
cells harvested from PDGFB-driven mGBM. In NIH 3T3 fibroblast
cells, encoding PDGFRα-myc receptors, we showed that 19F-SKI249380
inhibited receptor activity. 19F-SKI249380 inhibited tyrosine kinase
activity and phosphorylation of PDGFRα and reduced downstream
activation and phosphorylation of MAPK, PI3K, and Src kinase signal-
ing at higher concentrations (150 nM). Inhibition of receptor activity
has not been investigated in prior studies. Our results are consistent
with those of previous studies using glioma cell lines [7,8], showing
reductions in levels of key pathway intermediates (i.e., pSrc, pAkt), after
100 to 250 nM dasatinib. Specifically, we observed a pronounced and
sustained inhibition of pSrc kinase (>72 hours), as compared with
shorter-lived inhibition of other phosphorylated intermediates of
MAPK and PI3K pathways.
Cell cycle studies suggested that 19F-SKI249380 inhibited prolifera-
tion in primary glioma cells resulting from G1 arrest, with clear reduc-
tions in the %S phase cells at higher 19F-SKI249380 concentrations.
Apoptosis occurred to a lesser degree over the concentration range
tested. These mechanisms of action have not been consistently ob-
served for other tumor cell lines incubated with dasatinib. In one prior
study [8], glioma cell lines treated with dasatinib demonstrated mini-
mal G1 arrest, negligible increase in the S phase population, increases
in autophagic cell death, and an absence of apoptosis. These effects
were also observed for human ovarian cancer [37]. Dasatinib has
also been shown to induce apoptosis at nanomolar concentrations in
osteosarcomas [33]. Conversely, Johnson et al. [38] revealed dasatinib-
induced G1 phase arrest and apoptotic effects in non–small cell lung
cancer and head and neck squamous cell carcinoma.
The ability to flexibly adapt the formulation of clinically promising
drugs to improve their physicochemical and/or biologic properties,
coupled with metabolic imaging tools for sensitively quantifying pre-
clinical/clinical trial end points, will be crucial to the success of molec-
ular medicine. At present, prescribed drug dosing regimens for treating
tumors are based on patient body surface area or weight considerations
rather than on the metabolic/functional characteristics of the individual
tumor, as established by quantitative imaging approaches. A suitable
tracer formulation should exhibit optimum solubility properties under
physiologic conditions [39], demonstrate no adverse biologic effects,
and facilitate drug transport, delivery [40], and tumor localization.
Improvements in drug solubility may reduce peak concentrations of
the drug in the circulation, leading to more favorable pharmacokinetic
and metabolic profiles. Blood circulation times may be extended,
enhancing bioavailability and localization of pharmaceutical activity
to the target tissue. Reductions in the required drug dosage might then
be realized, thus minimizing risks of systemic toxicity while increasing
treatment efficacy.
In this study, utilization of micellar and liposomal nanocarriers met
these requirements. Additionally, the calculated CMC for our mi-
cellar preparations suggested that 18F-SKI249380, although initially
contained within micelles, should be released from this formulation,
largely existing in a free form during the course of the imaging study.
Thus, its uptake and distribution should be representative of that ob-
served for dasatinib. On the basis of the estimates of the whole-body
fluid compartment, PEG-PE concentrations in micelles were roughly
10 μM, on the order of the CMC. This property of micelles may
explain, along with its relatively smaller average size, the greater tumor
uptake/accumulation found with micellar tracer preparations of 18F-
SKI249380, compared with liposomal preparations. In addition, the
improved drug solubility, delivery, and kinetic behavior, conferred
by the use of these micellar 18F-SKI249380 preparations, presumably
contributed to these findings.
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Figure W1. PDGFB-driven mGBM cell survival and proliferation are inhibited by increasing concentrations of 19F-SKI249380 and dasatinib.
(A) Cell viability loss as a function of drug concentration in DMEM-HG media supplemented with 10% FCS. (B) Differences in viability
and growth rate of mGBM cells incubated with 19F-SKI249380 or dasatinib as a function of time at two different concentrations.
(C) 19F-SKI249380 reductions in the viability of mGBM cells initially quiescent (serum-deprived conditions) but subsequently induced
by 10% FCS–supplemented media. (D) Same as in C but induced by 0.2% FCS and PDGF-BB supplementation. Control wells contain
0.2% FCS. Experiments performed in triplicate.
Figure W2. 19F-SKI249380 promotes G1 arrest, marked reductions in S phase (proliferative phase) activity, and increased apoptosis.
(A) Percentage (%) of viable cells in the G1, S, and G2 phases of the cell cycle as a function of
19F-SKI249380 concentration. Representative
histograms (arrows) are shown for cells under control (i.e., no drug) conditions and after incubation with 1 μM19F-SKI249380. (B) Percentage
of apoptotic cells as a function of 19F-SKI249380 concentration. Representative histograms (arrows) for three drug concentrations indicate
percentage of apoptotic cells (lower right-hand corner). Experiments were performed in triplicate.
Figure W3. In vitro lipid formulations of 18F-SKI249380 for PDGFR targeting and characterization. (A) Schematic of a representative
micelle (left) and liposome (right). (B) Micelle (left) and liposome (right) size distribution by intensity.
Figure W4. MicroPET image–derived and ex vivo γ-counted bio-
distribution data following injection of glioma-bearing mice with
micelle nanoformulations of 18F-SKI249380. (A) Image-derived mean
uptake values for organs/tissues in glioma mice at various times
from15minutes to 4 hours after i.v. injection ofmicelle-encapsulated
18F-SKI249380. (B) Ex vivo uptake values for γ-counted tissues/
organs acquired 4 hours after injection. Inset: Correlation of in vivo
and ex vivo tissue %ID/g values at 4 hours p.i. Each bar represents
mean ± SD. Bl, blood; Tu, tumor; He, heart; Lu, lung; Liv, liver; Spl,
spleen; St, stomach;SI, small intestine; LI, large intestine; Kid, kidney;
Mus, muscle; Bo, bone.
